Closure May Lead to Medical Device Shortage & Impact Patients

October 25, 2019 06:06 PM Eastern Daylight Time

ATLANTA–( BUSINESS WIRE )–Georgia Bio member companies are dedicated to improving patients’ lives-enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Our member companies continually strive to exceed regulations and reduce their environmental footprint.

We are very concerned with the potential shut down of BD’s Covington facility over the use of EtO. Ethylene oxide is the safest, and sometimes, only method for ensuring the sterilization of medical devices for clinicians and patients. Approximately 50% of all medical devices are sterilized using EtO, accounting for more than 20 billion devices annually in the U.S. Many of our members manufacture devices and products that cannot be sterilized by any other means due to their complex nature, including pacemakers, implantable defibrillators, cardiac catheters, biopsy instruments and surgical fixation devices and vascular access devices including PICCs, midlines and ports. BD is the largest supplier of urinary catheters that are used in almost every surgical procedure that takes longer than 2 hours. They are also one of the only suppliers for pediatric vascular access devices used to deliver chemotherapy to children with cancer.

Georgia Bio believes policy makers have an obligation to protect the public from harmful emissions from any source, and we believe all industrial facilities in our state should meet or exceed safety standards. We support an open and transparent debate regarding EtO that is grounded in scientific fact, but caution that a hasty decision to close this facility or severely restrict the use of ethylene oxide would endanger the health of thousands, possibly even millions, of patients who are relying on sterile medical products.

About Georgia Bio

Georgia Bio is an independent, non-profit 501(c)(3) trade association whose mission is to advance the growth of Georgia’s life sciences industry and foster strategic partnerships that can create a healthier world. Georgia Bio member companies are dedicated to improving patients’ lives – enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Georgia Bio members include bioscience and medtech companies, academic and research institutions, life science service providers, digital health companies, and related organizations. For more information, visit  www.gabio.org  or follow us on  Twitter @Georgia_Bio.

Contacts

Joseph Santoro 
404-334-7538 
jsantoro@gabio.org

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: